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Background: There is completely no report about both hen egg anti-lipase immunoglobulin yolk (IgY) and its
anti-obesity action. Thus, we tried to isolate and characterize a novel anti-lipase immunoglobulin from hen egg yolk.
Moreover, we investigated whether hen egg yolk anti-lipase IgY inhibits pancreatic lipase activity in vitro, and
examined its ability to prevent obesity in a murine high fat diet-induced obesity model.
Methods: We determined the inhibitory action of Anti-lipase IgY on lipase activity in vitro. We also focused our
evaluation on the anti-obesity properties of Anti-lipase IgY in a murine high fat diet-induced obesity model.
Results: Anti-lipase IgY blocked porcine lipase activity with an IC50 of 0.49 μM. Supplementing the high fat diet
with only 0.2% (w/w) of Anti-lipase IgY for 35 days significantly decreased the weights of intraperitoneal adipose
tissues, epididymal, mesenteric, retroperitoneal and perirenal adipose tissues, and the amounts of hepatic total lipid,
triglyceride, and cholesterol. This was accompanied by a significant increase in the fecal excretion of triglyceride in
the absence of diarrhea. Furthermore, Anti-lipase IgY treatment restored body weight gain to levels similar to mice
fed with Control IgY.
Conclusions: This study provides the first report of the development of anti-lipase IgY and the direct evidence that
inhibition of pancreatic lipase using Anti-lipase IgY is an effective anti-obesity treatment due to the associated
increase in fecal excretion of triglyceride.
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Introduction
Obesity causes excess fat accumulation in several tissues
in addition to white adipose tissue (WAT), such as other
insulin-responsive organs including the skeletal muscle
and liver; this predisposes individuals to the develop-
ment of insulin resistance. Obesity is strongly associated
with metabolic syndrome, which is characterized by the
presence of insulin resistance, hypertension, and hyper-
lipidemia. Metabolic syndrome, which is closely linked
to atherosclerosis, has become a major public health
problem.* Correspondence: nagaoka@gifu-u.ac.jp
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stated.Several approaches for prevention and treatment of
obesity have been reported [1]. Among these, both nat-
ural and synthetic pancreatic lipase inhibitors are effect-
ive in obesity prevention, likely due to their inhibition of
intestinal lipid absorption. Indeed, a specific pancreatic
inhibitor, Orlistat, has been used in the clinic for the
prevention of obesity [2]. In animal studies, a major tea
catechin, (−)-epigallocatechin-3-gallate [3] and polyphe-
nol extracts in black tea [4] prevented high-fat diet-
induced obesity via the inhibition of pancreatic lipase.
Another innovative candidate approach for pancreatic
lipase inhibition is oral administration of anti-lipase im-
munoglobulin yolk (IgY) antibodies. There is completely
no report about both hen egg yolk anti-lipase IgY and its
anti-obesity action. Hens transfer immunoglobulin G
(IgG) in blood into the egg yolk to provide acquiredLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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http://www.nutritionandmetabolism.com/content/10/1/70immunity to the offspring; this transferred IgG is termed
IgY. The IgY technology offers several advantages over
other methods of antibody production. For example,
development and production of specific IgY can be
achieved through collecting eggs from hens immunized
with the target antigen, without the need for painful
blood sampling and sacrifice of the animals.
The stability of IgY in pressure, heat, pH, trypsin,
chymotrypsin, pepsin, and in the gastrointestinal tract
has been well-documented [5]. IgY is relatively stable
to pressure up to 4,000 kg per cm2. IgY is stable at
temperature ranging between 30°C and 70°C. It was found
that the activity range of IgY for pH was pH 3.5 ~11. The
stability of IgY at pH 3 was increased in the presence of
sorbitol [6]. IgY is quite resistant against trypsin and
chymotrypsin inactivation, but degraded by pepsin [7].
Moreover, our group has investigated the in vivo passage
and the efficacy of IgY in the gastrointestinal tract of
piglets and calves. Our results indicated that IgY powder
was transported as immunologically functional molecules
from the stomach down to the small intestine of calves
while retaining much of their original biological activity [8].
Exploiting the peculiarities of the avian immune
system, it is possible to mass-produce specific IgY anti-
body against various antigens, since IgY levels are ex-
tremely high in egg yolk, and one hen lays 250–300
eggs per year. Indeed, other scientists as well as we have
produced IgY antibodies against microorganisms such
as cholera [9] and Candida [10] using this method.
Furthermore, we have shown that oral passive immu-
nization with IgY antibodies prevented and improved
antigen-induced disease symptoms in animal studies
[11,12].
Here, we describe the production of a novel anti-lipase
specific IgY from egg yolk following immunization of
hens with a porcine pancreatic lipase, a key enzyme
required for lipid digestion. Since the oral passive IgY-
based immunotherapeutic strategy outlined above was
effective against bacteria, we predicted that our new ap-
proach would produce a selective inhibitor of pancreatic
lipase activity. By extension, we hypothesized that this
inhibitor may exert anti-obesity effects. Thus, in this
study, we investigated whether hen egg yolk anti-lipase
IgY inhibits pancreatic lipase activity in vitro, and exam-




The enzyme substrates and reagents were as follows: trio-
lein, taurocholate, colipase, and L-α-phosphatidylcholine
were from Sigma (MO, USA). High pure porcine pan-
creatic lipase was obtained from Elastin Products Co
(Owensville, MO, USA). The fresh porcine pancreas wasobtained from the local slaughtering house in Gifu, Japan.
Lipase purification procedure was based upon the method
of Garner and Smith [13]. Anti-porcine pancreas lipase-
specific IgY containing preparation (designated as Anti-
lipase IgY) and control IgY preparation (designated as
Control IgY) were kindly provided by EW Nutrition Japan.
(Gifu, Japan).
Anti-Lipase IgY preparation
Five-month-old White leghorn hens (Hyline W36; Japan
Layer, Gifu) were immunized according to the method
described by Yokoyama et al. [14]. Briefly, the vaccine
was prepared by mixing 0.5 mg of purified lipase antigen
with 0.5 ml emulsion oil containing 5% Arlacel 80 (Maine
Biological Laboratories, Waterville, Me, USA) and hens
were immunized by injecting 0.5 ml to each of the breast
muscles. Six weeks after the initial immunization, a booster
was given in the same manner. Eggs from the immunized
hens were harvested daily and stocked at 4°C. Egg yolk was
separated carefully from the albumin. The yolk was then
pooled, homogenized, and filtrated. Partially purified spe-
cific IgY powder was prepared by ammonium sulfate pre-
cipitation [15], and freeze-dry. Control IgY powder was
prepared from the egg of non-immunized hens by the
same method.
Assay to determine titer of anti-lipase specific IgY
The concentrations of both Anti-lipase IgY and Control
IgY were determined using an enzyme-linked immuno-
sorbent assay (ELISA) method as previously described [16].
Lipase activity assay
The porcine pancreatic lipase activity was determined
using the method of Tsujita et al. [17].
Animals and diets
Male 6-week-old C57BL/6 J mice were purchased from
Japan SLC (Hamamatsu, Japan). Mice were housed indi-
vidually in standard plastic rodent cages, and placed in a
room where the temperature was maintained at 22 ± 2.0°C
with a 12-h light:dark cycle (lights on 0800–2000 h). All
the mice consumed a commercial nonpurified MF (Mouse
Flat) diet (Oriental, Yeast, Osaka, Japan) and tap water ad
libitum for 4 days prior to their division into the following
two weight-matched groups (n = 8: 8 mice per group):
0.2% (w/w) Control IgY-supplemented diet (CY) group,
and 0.2% (w/w) Anti-lipase IgY-supplemented (AY) group.
The compositions of the experimental diets are shown in
Table 1. Mice were fed on these diets for 35 days. To de-
termine the effective dose of Anti-lipase IgY in mice, we
have done the preliminary experiment for 8 days. After
this preliminary experiment, we have chosen 0.2% (w/w)
of IgY in mouse study.




Control IgY 2 -
Anti-lipase IgY - 2
Corn starch 172 172
Sucrose 86 86
Cellulose 65 65




Choline chloride 4 4
1AIN-93G Mineral mixture.
2AIN-93G vitamin mixture.
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corded daily during the feeding period. At the end of the
experimental period, animals were anesthetized with
ether after a 22-h fasting period. Livers and visceral fat
pads were removed and weighed. The plasma, liver, and
visceral fat pad samples were collected and stored at −80°C
until analysis. Fecal collections (d 7–9) were used for deter-
mining fecal lipids. The care and experimental procedures
were approved by the Animal Care and Use Committee of
Gifu University.Biochemical analyses
Various lipid concentrations were determined using
commercially available kits as follows: plasma, liver, and
fecal triglyceride with Triglyceride E-test Wako (Wako
Pure Chemical, Osaka, Japan) and plasma, liver, and
fecal cholesterol with Cholesterol E-test Wako (Wako
Pure Chemical, Osaka, Japan). Liver and fecal lipids were
extracted by the method of Folch et al. [18], and total
lipids were determined gravimetrically by the method of
Nagaoka et al. [19].
Plasma glucose levels were determined by the glucose
CII test (Wako Pure Chemical, Osaka, Japan). Plasma in-
sulin levels were measured with an ELISA kit (Morinaga
Institute of Biological Science, Yokohama, Japan). Plasma
TNF-α levels were measured with an ELISA kit (R&D Sys-
tems, Minneapolis, USA).Figure 1 Effects of increasing concentration of Control IgY (○)
or Anti-lipase IgY (●) on pancreatic lipase activity. The values are
means ± SEM, n = 6. Differences from the Control IgY were
calculated using Student’s t test (*p < 0.05, **p < 0.01, ***p < 0.001).Statistical analyses
All data presented in this study were normally dis-
tributed. Data were tested for normal distribution by
the Kolmogorov-Smirnov normality test [20,21]. After
Kolmogorov-Smirnov test, the statistical significance of
differences was evaluated using the Student’s t-test [22].Results
Titer of anti-lipase specific IgY
The titers of Anti-lipase IgY (AY) or Control IgY (CY)
used for the mouse study were 25.72 ± 1.37 mg/g or
0 mg/g preparation, respectively.
Inhibitory effect on lipase activity
AY inhibited pancreatic lipase activity by 95.4〜18.3% at
concentrations between 10,000〜10 μg/ml, whereas CY
did not inhibit triolein hydrolysis by pancreatic lipase.
The IC50 value of AY was 88 μg/ml (0.49 μM). Growth
inhibition of pancreatic lipase occurred in a dose-
responsive manner (Figure 1).
Body weights, total food intake, fecal and tissue weights
Initial body weight, final body weight, body weight gains,
total food intake, fecal and liver weights were all un-
affected by dietary treatment (Table 2). The adipose tissue
(epididymal, mesenteric, retroperitoneal and perirenal)
weight was significantly lower in the AY group than that
of the CY group.
Plasma parameters, liver and fecal lipids
The plasma triglyceride tended to be lower (p = 0.093)
in the AY group than that of the CY group (Table 2).
Table 2 Effects of Control IgY (CY) and Anti-lipase IgY
(AY) on physiological parameters
CY AY
Initial body weight (g) 27.57 ± 0.27 22.50 ± 0.38
Final body weight (g) 26.18 ± 0.75 25.47 ± 1.01
Body weight gain (g/35 d) 3.61 ± 0.88 2.97 ± 0.85
Total food intake (g/35 d) 99.27 ± 4.81 95.28 ± 2.31
Fecal dry weight (g/3d) 0.96 ± 0.03 0.91 ± 0.02
Tissue weight (mg/g B.W.)
Liver weight 33.6 ± 0.64 34.7 ± 1.07
Epididymal WAT 26.8 ± 2.76 20.2 ± 0.40*
Mesenteric WAT 9.32 ± 0.94 6.57 ± 0.50*
Retroperitoneal WAT 14.0 ± 1.18 10.8 ± 0.41*
Perirenal WAT 9.51 ± 1.31 6.32 ± 0.40*
Intraperitoneal WAT 59.6 ± 5.74 43.9 ± 0.73*
Tissue weight (mg)
Liver weight 877.5 ± 22.6 877.6 ± 20.5
Epididymal WAT 709.9 ± 87.3 513.5 ± 20.4*
Mesenteric WAT 246.5 ± 29.9 169.0 ± 16.4*
Retroperitoneal WAT 332.0 ± 53.1 273.3 ± 13.0*
Perirenal WAT 251.6 ± 39.9 162.0 ± 13.5*
Intraperitoneal WAT 1573.4 ± 180.5 1117.8 ± 52.0*
Plasma parameters
Triglyceride (mg/dl) 54.2 ± 3.6 44.6 ± 3.9
Cholesterol (mg/dl) 109.1 ± 3.9 104.6 ± 3.4
Glucose (mg/dl) 134.7 ± 7.1 137.1 ± 7.2
Insulin (ng/ml) 0.14 ± 0.02 0.14 ± 0.02
TNF-α (pg/ml) 3.29 ± 0.12 3.66 ± 0.17
Liver lipids (mg/g liver)
Total lipids 132.6 ± 10.8 90.6 ± 7.9**
Triglyceride 51.9 ± 0.9 45.0 ± 2.6*
Cholesterol 6.77 ± 0.45 4.32 ± 0.17**
Fecal lipids (mg/3d)
Total lipids 71.4 ± 2.89 77.1 ± 2.48
Triglyceride 5.67 ± 0.32 7.50 ± 0.64*
Cholesterol 6.65 ± 0.35 6.72 ± 0.26
1. Each value is the mean ± SEM, n = 8.
2. Asterisks indicate significant differences as compared with mice fed a
high-fat diet containing control IgY by Student’s t-test (*p < 0.05; **p < 0.01).
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in the AY group than in the CY group. The fecal excre-
tion of triglyceride was significantly higher in the AY-
treated animals when compared with controls. Plasma
glucose, insulin and TNF-α levels were not significantly
changed between AY group and CY group.
Discussion
To begin the search for alternative anti-obesity agents,
we exploited a hen immunization model to produceAnti-lipase IgY, a novel antibody that recognizes porcine
pancreatic lipase. The lipolytic activity was strongly
inhibited in a concentration-dependent manner upon
addition of Anti-lipase IgY when compared with Control
IgY (Figure 1). These results suggest that Anti-lipase IgY
reacts specifically with pancreatic lipase. Surprisingly,
the IC50 of Anti-lipase IgY (0.49 μM) that elicits an anti-
obesity effect is approximately half that of Orlistat, which
has an IC50 of 0.96 μM [17]. Both of these treatments are
in turn superior to the green tea polyphenol, (−)-epigallo-
catechin gallate (EGCG), which has an IC50 of 7.5 μM [3]
accompanying an anti-obesity action in mice fed a high
fat diet. Interestingly, as the effective dose of IgY is 0.2%
(w/w) in animal study, it is the lowest value among func-
tional food components such as EGCG [3,4].
Recently, the availability of lipase inhibitor agent for
preventing metabolic syndrome has received much at-
tention. Orlistat, an anti-obesity drug used in the clinic,
is a potent and specific covalent inhibitor of digestive
lipase [2,23], which leads to reduced intestinal absorp-
tion of lipolysis products. However, the use of Orlistat
is frequently associated with gastrointestinal adverse
effects, such as oily stools, diarrhea, cholelithiasis and
cholestatic hepatitis [2,24]. But, judging from our obser-
vation and the data of liver lipids analysis, there is no
side effect by the treatment of anti-lipase IgY as observed
by Orlistat.
The effects of Anti-lipase IgY and Control IgY on
obesity were evaluated in mice fed a high-fat diet con-
taining 0.2% (w/w) IgY, respectively. Anti-lipase IgY
supplementation significantly decreased adipose tissue
weights and hepatic lipid levels and also significantly in-
creased the fecal excretion of triglyceride compared with
Control IgY feeding (Table 2). These results suggest an
anti-obesity function of Anti-lipase IgY: it inhibits the
hydrolysis of dietary fat in the small intestine and re-
duces intestinal absorption of dietary fat, which is then
excreted into the feces.
To investigate the effect of anti-lipase IgY on the ab-
sorption of triglyceride in the diet, we analyzed fecal
lipids contents. Previous study showed that lipase inhib-
ition by synthetic lipase inhibitor Orlistat was extremely
fast (half-inhibition time < 1 min) [25]. Moreover, in our
preliminary study, single anti-lipase IgY administration
tended to decrease in plasma triglyceride levels after sin-
gle gavage of olive oil. These results indicate that the
treatment with anti-lipase IgY for short term is effective
for the increase in fecal triglyceride content. Thus, we
performed fecal collection during day 7 through 9. On
the other hand, it seemed to need longer time before the
treatment with anti-lipase IgY become effective against
the other measurements, such as adiposity and hepatic
lipid accumulation. Thus, in this study, we investigated
the effects of anti-lipase IgY treatment for longer period
Hirose et al. Nutrition & Metabolism 2013, 10:70 Page 5 of 6
http://www.nutritionandmetabolism.com/content/10/1/70(35 days) on these parameters. Unfortunately, we have
no data about a timing effect on fecal lipid excretion,
and further investigation on it is important in future
study. However, to our knowledge, there is no report
about the tolerant to pancreatic lipase inhibitor, such as
Orlistat. Moreover, Moreno et al. reported that dietary
supplementation with peanuts shell extracts, which in-
hibit pancreatic lipase, significantly increased the excre-
tion of fecal lipids in rats fed a high fat diet at 3 weeks
of the study and the increase continued until the end of
the study, 12 weeks [26]. In addition, Desmarchelier et al.
reported that feeding mice a high fat Western diet con-
taining cholesterol remarkably increased the excretion
of fecal neutral sterol during day 4–11 of the experi-
ment and the increase was kept until late in the experi-
ments, day 74–81 [27]. These findings in the literatures
suggest that diet-, nutrient- and food ingredient-
stimulated enhancement of fecal lipid excretion ob-
served in early experimental stage could be sustained
even in late stage. Therefore, we determined fecal lipids
during the relatively early stage and found a significant
increase in the fecal triglyceride of mice treated with
anti-lipase IgY, which is predicted to be kept until the
late stage.
The aim of this study is to determine whether the
anti-lipase IgY has the preventive effects on early obesity
development. Obesity is defined as excessive fat accumu-
lation [28]. Thus, in this study, we mainly investigated
the effects of relatively short term treatment (35 days)
with the anti-lipase IgY on the high-fat diet-induced de-
velopment of white adipose tissues (WAT). Although
the treatment with anti-lipase IgY didn’t affect body
weight (tended to decrease but not significantly), we
demonstrated that the anti-lipase IgY inhibited visceral
WAT accumulation, and we evaluated that the anti-
lipase IgY has an anti-obesity effect. A similar claim was
made in the study done by Foucault AS et al. [29]. The
reason why anti-lipase IgY didn’t affect body weight gain
in this study may be due to the experimental period be-
cause circular triglyceride level in mice fed control HFD
in this study is not higher than those in mice fed HFD
for prolonged period in previous studies [30,31]. There-
fore, further investigation is needed about the effects of
anti-lipase IgY treatment for longer period on the body
weight gain and obesity-induced metabolic disorders, in
future. However, a specific pancreatic lipase inhibitor,
Orlistat, has been used in clinics for the prevention of
obesity [2], and Orlistat has been shown not only to pre-
vent body weight gain but also to improve obesity-
induced metabolic disorders, such as glucose intolerance
and diabetes [32]. Our results showed that anti-lipase
IgY has more potent inhibitory effect on the pancreatic
lipase than Orlistat (IC50 values: 0.49 μM vs 0.96 μM)
[17]. Thus, we think we can expect that anti-lipase IgYhas useful effect on body weight gain and obesity-
induced metabolic disorders in the prolonged treatment.
Taken all together, the data from our study show that
Anti-lipase IgY is a promising new lead biologic agent
for the development of functional foods and medicines
expected to prevent and improve obesity.
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